Clinical Trials Logo

Prehypertension clinical trials

View clinical trials related to Prehypertension.

Filter by:

NCT ID: NCT00553969 Completed - Pre-hypertension Clinical Trials

Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease

DETECT
Start date: November 2007
Phase: Phase 1/Phase 2
Study type: Interventional

This study will examine the individual and combined effects of Coreg CR and lisinopril, on cardiovascular health as measured by Rasmussen Disease Score (RDS) in a blinded, placebo controlled comparison over a 9-month study period. Patients to be randomized will have pre-hypertensive blood pressures that do not require anti-hypertensive therapy and at least one additional cardiovascular risk factor.

NCT ID: NCT00420342 Completed - Hypertension Clinical Trials

Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension

Start date: January 2007
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to compare the effects of treatment of two different formulations of Angeliq® and Prempro on blood pressure in post-menopausal women with prehypertension.

NCT ID: NCT00388388 Terminated - Pre-diabetes Clinical Trials

Losartan Versus Hydrochlorothiazide in Reversing Remodeling of Small Arteries in Pre-Hypertensive Pre-Diabetic Subjects

Start date: March 2007
Phase: Phase 2
Study type: Interventional

This randomized, double-blind, parallel group, two-centre pilot study will test the hypothesis that subjects who are otherwise healthy but fulfill the criteria for a diagnosis of pre-hypertension and pre-diabetes will have regression or reduced progression of hypertension-associated changes in their resistance arteries if their blood pressure is controlled for 6 months with losartan, whereas similar subjects whose blood pressure is equally well controlled using hydrochlorothiazide will have significantly less improvement of the changes in their resistance arteries.

NCT ID: NCT00288158 Completed - Obesity Clinical Trials

Primary Prevention of Hypertension in Obese Adolescents

Start date: September 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to examine the consequences of lowering serum uric acid in pre-hypertensive, obese adolescents pathways involved with how uric acid mediated hypertension and renal disease. The specific aims are: 1. Test the hypothesis that lowering uric acid will improve endothelial function. 2. Test the hypothesis that lowering uric acid will reduce plasma renin activity and serum angiotensin II levels. 3. Test the hypothesis that lowering uric acid will reduce markers of inflammation

NCT ID: NCT00170937 Completed - HYPERTENSION Clinical Trials

A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan (320 mg) and Hydrochlorothiazide (25 mg) Combined and Alone, in Patients With Metabolic Syndrome

Start date: November 2004
Phase: Phase 4
Study type: Interventional

The metabolic syndrome is a classification for patients with a constellation of risk factors which may include abdominal obesity, hypertension, elevated blood lipids and sugar. Three or more of these factors together constitute the metabolic syndrome and place these patients at a greater risk for the development of diabetes and cardiovascular diseases. The purpose of this study is to determine whether two common drugs to lower blood pressure, whether used separately or in combination, have different effects on blood sugar levels in patients diagnosed with the metabolic syndrome.

NCT ID: NCT00152074 Completed - Hypertension Clinical Trials

Salt Reduction on Blood Pressure and Cardiovascular Organ Damage

Start date: April 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the effect of a modest reduction in salt intake on blood pressure in white, black and Asian individuals with hypertension or prehypertension, and also to determine whether a modest reduction in salt intake has beneficial effects on the surrogate markers of target organ damage in cardiovascular disease.